Prodrugs, Metabolic Stability and Drug Development

Prodrug Design

A prodrug is a pharmacologically inactive or less active compound that is converted in vivo to an active drug by enzymatic or chemical transformation. Prodrug strategies address poor oral bioavailability, instability, toxicity, poor membrane permeability, or site-specific delivery. Ester prodrugs are the most common: esterases cleave the ester bond in the intestinal wall or liver to release the active acid. Examples: enalapril (ester prodrug of enalaprilat — an ACE inhibitor; enalaprilat is too polar for oral absorption); oseltamivir (ethyl ester prodrug of oseltamivir carboxylate); valaciclovir (valine ester of aciclovir — 3-5× better oral bioavailability).

Metabolic Stability

Hepatic first-pass metabolism significantly reduces bioavailability of many drugs. Cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9) oxidise lipophilic drugs. Strategies to improve metabolic stability: (1) Fluorination — replacing a metabolically labile C-H bond with C-F is resistant to oxidation (e.g. fluoxetine); (2) Deuterium substitution — C-D bond is 6-10× harder to break than C-H (deutetrabenazine); (3) Ring closure — reducing rotatable bonds; (4) Blocking the site of metabolism — adding bulky groups at the vulnerable position.

Drug Development Pipeline

Drug development proceeds from target identification → hit finding (high-throughput screening or fragment-based drug discovery) → lead optimisation (SAR, ADMET profiling) → preclinical development (in vitro/in vivo safety and PK) → Phase I clinical trials (healthy volunteers, safety, PK) → Phase II (efficacy, dose-finding, small patient population) → Phase III (large randomised controlled trial, efficacy and safety) → regulatory submission and approval → Phase IV (post-marketing surveillance). The average development timeline is 10-15 years with a cost of over USD 1 billion per approved drug. Fewer than 1 in 10,000 screened compounds reaches the market.